Schering-Plough's Temodal improves glioblastoma multiforme survival

By Jennifer Chiou

New York, Oct. 31 - Schering-Plough Corp.'s Temodal following radiation therapy boosted median survival in patients with newly diagnosed glioblastoma multiforme after surgery, according to data presented at the European Cancer Conference.

The company noted an 18.3-month median survival was observed in patients who underwent complete resection followed by Temodal and radiation compared with 14.2 months for those receiving radiation alone.

The 573-patient study was conducted by the European Organisation for Research and Treatment of Cancer with the National Cancer Institute of Canada Clinical Trials Group.

"Our expectations were exceeded in this study, particularly among patients who underwent complete resection followed by Temodal and radiation therapy," principle study investigator Martin van den Bent said in a news release.

"Median patient survival increased as much as four months in this study, which is a benefit for patients living with this devastating disease."

Based in Kenilworth, N.J., Schering-Plough is a health care company with leading prescription, consumer and animal health products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.